Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans

Clinical Pharmacokinetics

Volumn 40, Issue , 2001, Pages 57-62

  Stass, Heino ^a   Kubitza, Dagmar ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATION; ERYFER 100; FERROUS SULFATE; MOXIFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHELATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; IRON THERAPY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; FERROUS COMPOUNDS; FLUOROQUINOLONES; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; QUINOLINES;

EID: 0035073796     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140001-00008     Document Type: Article

References (5)

1. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42:410-25
2. Blondeau JM, Felmingham D. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens. Clin Drug Invest 1999; 18: 57-78
3. Lomaestro BM, Bailie GR. Absorption interactions with fluoroquinolones. 1995 update. Drug Saf 1995; 12: 314-33
4. Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother 1990; 26 Suppl. D: 7-29
5. Knupp CA, Barbhaiya RH. A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic. Biopharm Drug Dispos 1997; 18: 65-77